Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 TKYMF | Basic Materials | $26.41 | 0.00 | $1.74B | 13.87 | 3.12% | ― |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| TKYMF | Tokuyama | 26.41 | -0.29 | -1.09% |
| Name | Price | % Change | |
|---|---|---|---|
| TKYMF | $26.41 | -1.09% |
Tokuyama ( ($JP:4043) ) has issued an announcement. Tokuyama has revised its consolidated earnings forecast for fiscal 2026, keeping net sales and operating profit unchanged but lifting profit attributable to
The latest update is out from Tokuyama ( ($JP:4043) ). Tokuyama reported higher net sales in the second quarter of fiscal 2026, supported by the consolidation of the Tokuyama Life
Tokuyama ( ($JP:4043) ) has provided an announcement. Tokuyama reported second-quarter fiscal 2026 consolidated net sales of 178.7 billion yen, up 9.1% year on year, but operating profit fell 29.2%
Tokuyama ( ($JP:4043) ) just unveiled an update. Tokuyama Corporation will absorb its wholly owned subsidiary Super Nano Design Co., Ltd., which develops synthesis recipes and provides custom synthesis services
Tokuyama ( ($JP:4043) ) has issued an announcement. Tokuyama has completed the previously announced spin-off and sale of its domestic cement and solidification agents sales business, transferring these operations and
Tokuyama ( ($JP:4043) ) has issued an announcement. Tokuyama Corporation has issued its previously undetermined performance and dividend forecasts for the fiscal year ending March 31, 2027, projecting consolidated net
Tokuyama ( ($JP:4043) ) has shared an update. Tokuyama reported that first-quarter fiscal 2026 net sales rose year on year, supported by the consolidation of the Tokuyama Life Science Group
Tokuyama ( ($JP:4043) ) has shared an update. Tokuyama Corporation reported first-quarter fiscal 2026 consolidated net sales of ¥85.7 billion, up 4.7% year on year, while operating profit fell 22.9%
Tokuyama ( ($JP:4043) ) just unveiled an update. Tokuyama has established a wholly owned subsidiary, Tokuyama Cement Corporation, to assume its domestic sales business for cement and solidification agents as
Tokuyama ( ($JP:4043) ) just unveiled an announcement. Tokuyama will introduce an employee stock grant system using an Employee Stock Ownership Plan trust for its own staff and those of
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| TKYMF | Jan 29, 2027TBA | $1.74B | ― | $648.77M | -2.39 | 13.87 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
